tirzepatide upset stomach Diarrhea on (Mounjaro) affects approximately 23–31% of patients and is typically mild to moderate, transient, and most common during dose escalation. , It rarely requires discontinuation Does Tirzepatide Slow Gastric Emptying?

Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist licensed in the UK for type 2 diabetes mellitus, offering significant glycaemic control and weight reduction

Precose (acarbose) Prescribing information

Characterization of the glucagon like peptide-1 receptor in male mouse brain using a novel antibody and in situ hybridization

if you are concerned about this, discuss it with your prescribing clinician before making changes Gut microbiome composition emerging research suggests associations between gut bacteria and fat metabolism, though the clinical applicability of this evidence is still developing Consistency and duration visceral fat loss is progressive